Enliven Takes Precision Oncology Ambitions Public In Merger With Imara

 
• By Joseph Haas

The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top candidate tovinontrine.

Enliven Imara merger
Enliven will reverse merge with troubled Imara in an all-stock deal • Source: Shutterstock

More from Deals

More from Business